Key Highlights

  • On November 10, 2026, Veradermics (NYSE:MANE) released third-quarter 2026 results and said its Phase 3 Study 304 in men achieved every primary and secondary endpoint.
  • Hair count increased by 36.4 hairs per square centimetre at month six on twice-daily dosing, against 28.6 on once-daily dosing.
  • Over the 12-month extension of Study 302, twice-daily patients gained 43.9, and 89.1% of them showed visible improvement.
  • The company recorded a net loss of USD 21.0 million and held USD 798.4 million in cash and securities at the end of September, sufficient to finance operations into 2030.

Trial Results in Detail

VDPHL01, the lead candidate of Veradermics (NYSE:MANE), is an extended-release oral version of minoxidil aimed at pattern hair loss. Topical minoxidil has existed for decades and dermatologists increasingly prescribe low-dose oral forms, yet no oral product holds approval for hair loss. Study 304 Part A satisfied every primary and secondary endpoint. Scalp coverage was rated improved or much improved in 68.7% of twice-daily patients and 55.7% of once-daily patients, in addition to the hair count results. Rather than levelling off, the 12-month Study 302 continuation showed more progress: hair count rose 43.9 on twice-daily dosing and 29.7 on once-daily dosing, with visible improvement in 89.1% and 79.8% of patients. No treatment-related serious adverse events and no new safety signals were reported, which matters because systemic minoxidil can influence blood pressure and heart rate. Regulators and physicians alike will lean on a steady safety record across two large studies.

Balance Sheet and Spending

Third-quarter net loss reached USD 21.0 million, against USD 20.1 million in the prior-year period. Research and Development expense declined to USD 16.1 million from USD 18.1 million as trial enrolment wound down. General and administrative expense jumped to USD 12.7 million from USD 2.3 million, which reflects public-company costs and early commercial planning. With USD 798.4 million in cash, equivalents and marketable securities, the runway extends into 2030 and should cover the remaining trials, a regulatory filing and the opening phase of a launch, with no obvious need to issue more equity. For a single-asset company that is an unusual position, and it removes one of the chief risks that tend to burden small biotech shares after a data release. It could also strengthen management's hand if it opts to find a commercial partner instead of launching alone.

Market Potential and Risks

Hair loss is a big consumer-health category where many buyers pay out of pocket, so pricing and direct-to-consumer Marketing will count for more than reimbursement. A branded oral product could capture Demand now served by compounded or off-label low-dose minoxidil, though that inexpensive option is also the main competitive threat, and physicians may doubt that a Brand deserves a premium. Study 306 in women has finished enrolment and is due to report in the first half of 2027, which could widen the label. Canadian investors who hold Veradermics (NYSE:MANE) through a brokerage that offers US-listed shares will want to follow the filing timeline, the women's data and any hint on pricing. Showing that the extended-release design causes fewer side effects than generic tablets would help support a branded price. A cosmetic indication is unlikely to win insurance coverage, so the launch may look like other self-pay medicines sold via telehealth and dermatology clinics.

Where Things Stand

Veradermics delivered hair count gains of 36.4 hairs per square centimetre at six months in its Phase 3 men's study, with added gains at 12 months and no new safety signals. Cash of USD 798.4 million funds operations into 2030. The women's study readout in the first half of 2027 and the regulatory filing are the next milestones, and cheap off-label minoxidil remains the main commercial test. Over the coming year the stock will probably respond to regulatory news and early launch planning.